Stocks Health care BDSX
NASDAQ · Health careBiodesix Inc (BDSX)
Biodesix Inc brought in $105.2M of revenue over the twelve months to September 30, 2026, up 31.2% from a year earlier. It posted a net loss of $27.1M. In fiscal 2025 capital spending exceeded operating cash flow by $23.5M. At September 30, 2026 it held $28.4M in cash against $50M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Biodesix Inc
- Net worth
- Biodesix Inc has a market value (market cap) of $90M at the latest share price, and shareholders' equity of $8.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $88.5M (+24.1% year on year), with a net loss of $35.3M. Over the 12 months to September 30, 2026: revenue $105.2M, net loss $27.1M.
- Cash flow
- In fiscal 2025 operations used $23.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Biodesix Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Biodesix Inc does
Biodesix Inc is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker BDSX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $88.5M | -$35.3M | -$4.67 | -$23.5M |
| 2024 | $71.3M | -$42.9M | -$6.64 | -$51.9M |
| 2023 | $49.1M | -$52.1M | -$12.88 | -$45.8M |
| 2022 | $38.2M | -$65.4M | -$31.19 | -$48.3M |
| 2021 | $54.5M | -$43.2M | -$31.79 | -$30.5M |
| 2020 | $45.6M | -$65.4M | -$130.39 | -$23.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BDSX ranks in Health care
Latest SEC filings
What Biodesix Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 10% to $24M versus the same quarter last year; diluted EPS -$0.75 versus -$1.16.
- November 5, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 34% to $26.9M versus the same quarter last year; diluted EPS -$0.71 versus -$1.56.
- August 5, 2026
- June 18, 2026Passive stake (5% or more) SCHEDULE 13G
- May 21, 2026
- May 20, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 8, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Biodesix Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Patience JohnDirector | Exercised options | 1,360 | - |
| August 12, 2026 | Schuler Jack W10% owner | Boughtindirect | 15,000 | $367K |
| August 11, 2026 | Schuler Jack W10% owner | Boughtindirect | 13,700 | $328.9K |
| August 10, 2026 | Schuler Jack W10% owner | Boughtindirect | 13,900 | $337K |
| June 30, 2026 | Patience JohnDirector | Exercised options | 1,361 | - |
| March 31, 2026 | Patience JohnDirector | Exercised options | 1,361 | - |
| February 23, 2026 | O'Kane KieranChief Commercial Officer | Sold | 535 | $6.8K |
| February 23, 2026 | Pestano Gary AnthonyChief Development Officer | Sold | 556 | $7.1K |
Who owns BDSX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Schuler Jack W13D, may seek influence with 2 related filers | 24% | January 27, 2026 |
| Jack W. Schuler13D, may seek influence with 1 related filers | 21.4% | May 23, 2024 |
| Lawrence T. Kennedy, Jr.13D, may seek influence with 3 related filers | 17.6% | May 23, 2024 |
| Orin Hirschman13G, passive with 1 related filers | 7.7% | April 28, 2026 |
| John Patience13D, may seek influence with 1 related filers | 6.7% | April 9, 2024 |
| Telemark Asset Management, LLC13G, passive with 2 related filers | 5.4% | January 26, 2026 |
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 5.1% | June 18, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 45 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| AIGH Capital Management LLC | 678,328 | -80,000 |
| Soleus Capital Management, L.P. | 585,958 | +169,359 |
| Telemark Asset Management, LLC | 489,824 | 0 |
| Aberdeen Group plc | 388,639 | -69,799 |
| Birchview Capital, LP | 286,804 | 0 |
| Vanguard Capital Management LLC | 284,169 | +29,008 |
| Essex Investment Management Co LLC | 241,915 | +109,829 |
| Opaleye Management Inc. | 180,000 | -58,047 |
| Marshall Wace, Llp | 116,199 | -25,437 |
| Perceptive Advisors LLC | 108,694 | new |
| Jane Street Group, LLC | 91,506 | +64,475 |
| Two Sigma Investments, LP | 86,824 | +41,593 |
| Legato Capital Management LLC | 81,381 | +40,207 |
| Walleye Capital LLC | 74,447 | +63,607 |
| Stempoint Capital LP | 70,000 | -70,008 |
| Geode Capital Management, LLC | 67,657 | +17,659 |
| Trexquant Investment LP | 57,972 | -11,629 |
| Perkins Capital Management Inc | 44,618 | -165 |
| BlackRock, Inc. | 43,026 | +18,560 |
| Blair William & Co | 41,548 | +13,965 |
Insiders
7 insiders reported holding 669,315 shares in total, about $5.7M at the last price.
| Holder | Shares |
|---|---|
| Schuler Jack W10% owner | 555,810555,810 held indirectly |
| Hutton ScottPresident & CEO, Director | 48,767 |
| Patience JohnDirector | 26,743 |
| Cowie Robin HarperCFO, Sec'y & Treasurer | 16,231 |
| Pestano Gary AnthonyChief Development Officer | 10,359 |
| O'Kane KieranChief Commercial Officer | 9,819 |
| Vazquez ChrisChief Accounting Officer | 1,586 |
Questions about BDSX
What does Biodesix Inc do?
Biodesix Inc is a company in the Health care sector, listed on NASDAQ as BDSX. Its shares trade on NASDAQ under the ticker BDSX.
What is Biodesix Inc's net worth?
Biodesix Inc has a market value (market cap) of $90M at the latest share price, and shareholders' equity of $8.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Biodesix Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $27.1M on revenue of $105.2M.
How much revenue does Biodesix Inc make?
Over the twelve months to September 30, 2026 Biodesix Inc reported revenue of $105.2M. That is 31.2% more than a year earlier.
When did Biodesix Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Biodesix Inc's next earnings report?
Biodesix Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BDSX with
Follow BDSX
Get an email when Biodesix Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Biodesix Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.